MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejphar.2026.178838

Медицинская библиотека · European journal of pharmacology · 2026

Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.

Du Lingzhi, Wang Jiahao, Wang Ying, Wang Hang, Xu Xianglai, Wang Jiajun

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Predicting response to immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO + TKI) therapy in metastatic renal cell carcinoma (mRCC) remains challenging. Forkhead box protein O1 (FOXO1) is a key transcription factor regulating tumor suppression and T cell immunity, but its clinical and immunological significance in RCC is unclear.

METHODS

FOXO1 expression was analyzed in TCGA-KIRC, ZS-MRCC, ZS-HRRCC, and JAVELIN Renal 101 cohorts. Associations with tumor grade, stage, survival, and IO + TKI response were evaluated. Immune infiltration and T cell functional states were assessed using immunohistochemistry and flow cytometry. An RF-based machine learning model incorporating FOXO1 and immune-related gene features was developed to predict therapeutic benefit.

RESULTS

FOXO1 expression was markedly reduced in RCC tissues and declined with increasing tumor grade and stage. Higher FOXO1 levels were associated with improved overall survival and better IO + TKI response. FOXO1-high tumors exhibited an immune-supportive microenvironment characterized by a trend toward increased cytotoxic CD8+ T cells, decreased CD4+ T cells, reduced exhausted T cells, lower macrophage infiltration, and favorable cytokine profiles. High FOXO1 expression also correlated with fewer BAP1 and BRAF mutations. FOXO1 independently predicted greater IO + TKI benefit (p for interaction = 0.019), and the RF risk score integrating multiple immune gene features achieved a more robust treatment interaction (p for interaction = 0.002).

CONCLUSION

FOXO1 carries both prognostic and predictive relevance in mRCC and independently predicts greater benefit from IO + TKI therapy. Integration of FOXO1 with complementary immune gene features into an RF-based model provides a promising framework for precision immunotherapy in advanced RCC.

Для цитирования: Du Lingzhi, Wang Jiahao, Wang Ying, Wang Hang, Xu Xianglai, Wang Jiajun. Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.. European journal of pharmacology. 2026. DOI: 10.1016/j.ejphar.2026.178838.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.